To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Laboratory | Nanomedicine | Nanosciences | Chemistry
The Nanosciences group is mainly involved in four research topics :
This collaboration has led us to develop a strategy for the recycling of an industrial by-product into a high added value alkaloid, to develop an alternative route for the preparation of the last generation anticancer drug "Vinflunine" (patent CEA / Pierre Fabre), and to achieve the first chemical synthesis of (+)-Catharanthine which is a key alkaloid from the Madagascar periwinkle. Enantioselective synthesis of (+)-Mequitazine (antihistaminic, Primalan®) and Lévomilnacipran (anti-depressant marketed as racemate, Ixel®) have also been developed in recent years.
It led to the development of a method for the separation of metallic from semiconducting nanotubes, the construction of hybrid materials for optical limiting and the design of nanosensors. Carbon nanotubes are currently also used as heterogeneous catalysts and for therapeutics.
Different systems have been conceived to provide the required stability and make nanocrystals addressable.
The micellar nano-objects are reinforced by a post-assembly photopolymerization process.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.